Dr Lal Pathlabs Ltd
Wed 21/05/2025,15:57:20 | NSE : LALPATHLAB
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 2835.00
Previous Close
₹ 2821.30
Volume
154824
Mkt Cap ( Rs. Cr)
₹23699.93
High
₹ 2885.00
Low
₹ 2803.50
52 Week High
₹ 3653.95
52 Week Low
₹ 2293.55
Book Value Per Share
₹ 239.45
Dividend Yield
0.85
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Dr Lal Pathlabs Ltd
Your Vote -
Buy
74.53%
Hold
3.73%
Sell
21.74%
74.53%
161 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
2835.20
124
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
124
Option Chain
Analyzes market sentiment, predicts Dr Lal Pathlabs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Dr. Lal Pathlabs Ltd - Disclosure under SEBI Takeover Regulations
-
Dr. Lal Pathlabs Ltd - Amended Trust Deed
-
Dr. Lal Pathlabs Ltd - Updates
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Lal Pathlabs Ltd has declared 60% Final dividend for the financial year March 2025
-
Dr. Lal Pathlabs Ltd - Copy of Newspaper Publication
-
Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Dr. Lal Pathlabs Ltd - Copy of Newspaper Publication
-
Dr. Lal Pathlabs Ltd - Outcome of Board Meeting-XBRL
-
Dr. Lal Pathlabs Ltd - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Lal Pathlabs Ltd - Press Release
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Dr. Lal Pathlabs Ltd Q4 net profit jumps 65.81% at Rs 148.40 cr
-
Dr. Lal Pathlabs Ltd - Annual General Meeting
-
Dr. Lal Pathlabs Ltd - General Updates
-
Dr. Lal Pathlabs Ltd - Appointment Of Auditors Viz. Internal Auditor, Cost Auditor And Secretarial Auditor
-
Dr. Lal Pathlabs Ltd - General Updates
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Change in Directorate
-
Dr. Lal Pathlabs Ltd - Record Date For Final Dividend For The Financial Year Ended March 31, 2025
-
Dr. Lal Pathlabs Ltd - Change in Director(s)
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Dividend Updates
-
Dr. Lal Pathlabs Ltd - Record Date
-
Dr. Lal Pathlabs Ltd - Board Meeting Outcome for Outcome Of Board Meeting Dated April 25, 2025
-
Dr. Lal Pathlabs Ltd - Outcome of Board Meeting
-
Dr. Lal Pathlabs Ltd - Dividend
-
Dr. Lal Pathlabs Ltd - Financial Results For The Quarter And Financial Year Ended March 31, 2025
-
Dr. Lal Pathlabs Ltd - Outcome of Board Meeting
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Credit Rating
-
Dr. Lal Pathlabs Ltd - Credit Rating
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Lal Pathlabs Ltd - Trading Window-XBRL
-
Dr. Lal Pathlabs Ltd - Board Meeting Intimation
-
Dr. Lal Pathlabs Ltd - Board Meeting Intimation for Considering And Approving The Audited Financial Results Of The Company Fo
-
Dr. Lal Pathlabs Ltd - Press Release
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Dr. Lal Pathlabs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Dr. Lal Pathlabs Ltd - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Dr. Lal Pathlabs Ltd - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Dr. Lal Pathlabs Ltd - Grant Of Stock Options
-
Dr. Lal Pathlabs Ltd - ESOP/ESOS/ESPS
-
Dr. Lal Pathlabs Ltd - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Change in Directorate
-
Dr. Lal Pathlabs Ltd - Cessation
-
Dr. Lal Pathlabs Ltd - Trading Window-XBRL
-
Dr. Lal Pathlabs Ltd - Trading Window
-
Dr. Lal Pathlabs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Dr. Lal Pathlabs Ltd - Update-Acquisition/Scheme/Sale/Disposal-XBRL
-
Dr. Lal Pathlabs Ltd - Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited (A Wholly Owned Subsid
-
Dr. Lal Pathlabs Ltd - General Updates
-
Dr. Lal Pathlabs Ltd - Announcement under Regulation 30 (LODR)-Credit Rating
-
Dr. Lal Pathlabs Ltd - Credit Rating- Others
-
Dr. Lal Pathlabs Ltd - Shareholders meeting
-
Dr. Lal Pathlabs Ltd - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Dr Lal Pathlabs
-
Dr. Lal PathLabs
-
Metropolis, Dr Lal Pathlabs, Thyrocare Technologies
-
Metropolis Healthcare, Dr Lal Pathlabs, Thyrocare Technologies
-
Metropolis, Dr Lal Path labs, Thyrocare
Key fundamentals
Evaluate the intrinsic value of Dr Lal Pathlabs Ltd stock
Name | March-25 | March-24 | March-23 | March-22 | March-21 |
---|---|---|---|---|---|
Assets | 2134.2 | 1982.996 | 1926.535 | 1821.892 | 1217.085 |
Liabilities | 2134.2 | 1982.996 | 1926.535 | 1821.892 | 1217.085 |
Equity | 83.6 | 83.478 | 83.368 | 83.345 | 83.345 |
Gross Profit | 665.5 | 559.24 | 460.701 | 510.217 | 407.38 |
Net Profit | 497.3 | 384.37 | 292.358 | 344.054 | 280.106 |
Cash From Operating Activities | 540 | 477.599 | 427.531 | 423.81 | 373.357 |
NPM(%) | 21.14 | 19.54 | 16.52 | 18.37 | 18.79 |
Revenue | 2351.6 | 1966.758 | 1769.03 | 1872.706 | 1490.555 |
Expenses | 1686.1 | 1407.518 | 1308.329 | 1362.489 | 1083.175 |
ROE(%) | 24.84 | 19.2 | 14.6 | 17.18 | 13.99 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
06 Jun 2025 | 6 | 60 | 0.85 | 2911.2 |
05 Feb 2025 | 6 | 60 | 0.85 | 2877.85 |
05 Nov 2024 | 6 | 60 | 0.85 | 3255.7 |
20 Aug 2024 | 6 | 60 | 0.85 | 3274.6 |
10 Jun 2024 | 6 | 60 | 0.85 | 2347.9 |
13 Feb 2024 | 12 | 120 | 0.85 | 2499.6 |
11 Aug 2023 | 6 | 60 | 0.85 | 1906.35 |
05 Aug 2022 | 6 | 60 | 0.85 | 2144.5 |
22 Jun 2022 | 6 | 60 | 0.85 | 2184.6 |
18 Aug 2021 | 6 | 60 | 0.85 | 3556.35 |
20 Jul 2021 | 8 | 80 | 0.85 | 2830.9 |
09 Feb 2021 | 6 | 60 | 0.85 | 2247.5 |
18 Nov 2020 | 6 | 60 | 0.85 | 2318.65 |
05 Mar 2020 | 6 | 60 | 0.85 | 1649.75 |
20 Nov 2019 | 6 | 60 | 0.85 | 1452.9 |
02 Aug 2019 | 3.5 | 35 | 0.85 | 1065.35 |
19 Nov 2018 | 2.5 | 25 | 0.85 | 880.5 |
03 Aug 2018 | 3 | 30 | 0.85 | 807.1 |
20 Nov 2017 | 1.5 | 15 | 0.85 | 833.75 |
12 Jul 2017 | 1.7 | 17 | 0.85 | 891.15 |
13 Feb 2017 | 1.3 | 13 | 0.85 | 1082.3 |
20 Jul 2016 | 2.45 | 24.5 | 0.85 | 941.5 |
Peers
Other companies within the same industry or sector that are comparable to Dr Lal Pathlabs Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 810.15 | -0.84 | 26.88 | 1609.52 | 301.39 | 0.62 |
Lotus Eye Hospital and Institute Ltd | 74.06 | 0.78 | 308.58 | 5864.87 | 14.01 | 0.68 |
Vaishali Pharma Ltd | 12.85 | -1.15 | 428.33 | 3022.98 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 701.25 | -1.59 | 0.00 | 5530.07 | -687.11 | 0.00 |
Company Info
Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company. 2016 -Dr Lal PathLabs Presents First Trimester Screening Test for Screening Prenatal Disorders -Dr Lal PathLabs Enhanced Liver Fibrosis Test For Mapping Liver Functionality -Dr Lal PathLabs is the First Private Lab in India to Introduce Electron Microscopy 2017 -Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited 2018 -Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab 2021 -Dr Lal PathLabs Launches Bangalore Reference Laboratory. 2023 -NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited. 2024 -NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.
Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently, Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory', pursuant to a partnership deed dated March 21, 1975, with the partnership deemed to have commenced from December 1, 1974. The partnership firm was formed to provide pathology services under the name `Central Clinical Laboratory' and to maintain a blood bank for the supply of blood to patients and hospitals under the name `Blood Transfusion Centre', both to be undertaken at the Registered Office of the Company. On December 5, 1977, following the demise of Late Dr. Major S.K. Lal, Late Ms. Vimla Lal, wife of Late Dr. Major S.K. Lal, was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal's demise, Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2, 2007. Accordingly, as on date, Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as `Dr. Lal PathLabs Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7, 2015. Consequently, the name of the Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. Awards and accreditations : 2001 -Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials. 2002 -Fully accredited by the College of American Pathologists' Laboratory Accreditation Program. 2008 -Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010 -Franchisor of the Year in healthcare, at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012 -Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013 -Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014 -Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories - Requirements for Quality and Competence" for medical testing, for National Reference Laboratory. 2015 -Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India. Major events and milestones : 2005 & 2007 -Investment by WestBridge I Investments Holdings. 2008 -Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013 -Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013 -Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014 -Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015 -Amalgamation of Sanya Chemicals Private Limited, Amolak Diagnostics Private Limited, Medex Healthcare Private Limited, Medicave Diagnostic Centre Private Limited, Medicave Medical Systems Private Limited and the Company. 2016 -Dr Lal PathLabs Presents First Trimester Screening Test for Screening Prenatal Disorders -Dr Lal PathLabs Enhanced Liver Fibrosis Test For Mapping Liver Functionality -Dr Lal PathLabs is the First Private Lab in India to Introduce Electron Microscopy 2017 -Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited 2018 -Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab 2021 -Dr Lal PathLabs Launches Bangalore Reference Laboratory. 2023 -NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited. 2024 -NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.
Read More
Parent Organisation
Dr. Lal Pathlabs Ltd.
Founded
14/02/1995
Managing Director
Dr.Om Prakash Manchanda
NSE Symbol
LALPATHLABEQ
FAQ
The current price of Dr Lal Pathlabs Ltd is ₹ 2835.20.
The 52-week high for Dr Lal Pathlabs Ltd is ₹ 2885.00 and the 52-week low is ₹ 2803.50.
The market capitalization of Dr Lal Pathlabs Ltd is currently ₹ 23699.93. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Dr Lal Pathlabs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Dr Lal Pathlabs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Dr Lal Pathlabs Ltd shares.
The CEO of Dr Lal Pathlabs Ltd is Dr.Om Prakash Manchanda, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.